The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2018 | Key updates in MPNs from ASH 2018
Claire Harrison, MD, FRCP, FRCPath, of the Guy’s and St Thomas’ NHS Foundation Trust, London, UK, gives her perspective on the latest data in myeloproliferative neoplasms (MPNs) from the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA. Key highlights include driver mutations, prognostics, and longer-term data from the MAJIC study (ISRCTN61925716).
